These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8749895)

  • 1. Maintenance medication for schizophrenia and schizoaffective patients.
    Lerner V; Fotyanov M; Liberman M; Shlafman M; Bar-El Y
    Schizophr Bull; 1995; 21(4):693-701. PubMed ID: 8749895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
    Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
    Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study.
    Procyshyn RM; Barr AM; Flynn S; Schenk C; Ganesan S; Honer WG
    Schizophr Res; 2010 Nov; 123(2-3):273-5. PubMed ID: 20688481
    [No Abstract]   [Full Text] [Related]  

  • 5. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic acid and Carbamazepine: a successful antipsychotic medication? The problem of diagnosis and its relevance for therapy.
    Gutiérrez K; Walter H; Bankier B
    Psychopathology; 1999; 32(5):235-41. PubMed ID: 10494062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness.
    Valenstein M; Kavanagh J; Lee T; Reilly P; Dalack GW; Grabowski J; Smelson D; Ronis DL; Ganoczy D; Woltmann E; Metreger T; Wolschon P; Jensen A; Poddig B; Blow FC
    Schizophr Bull; 2011 Jul; 37(4):727-36. PubMed ID: 19933540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.
    Simhandl C; Meszaros K
    J Psychiatry Neurosci; 1992 Mar; 17(1):1-14. PubMed ID: 1349823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
    Morrissette DA; Stahl SM
    CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effects of Psychoeducation on Long-term Inpatients with Schizophrenia and Schizoaffective Disorder.
    Yanagida N; Uchino T; Uchimura N
    Kurume Med J; 2017 May; 63(3.4):61-67. PubMed ID: 28381728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders.
    Janssen B; Gaebel W; Haerter M; Komaharadi F; Lindel B; Weinmann S
    Psychopharmacology (Berl); 2006 Aug; 187(2):229-36. PubMed ID: 16710714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knowledge and insight in relation to functional remission in patients with long-term psychotic disorders.
    Alenius M; Hammarlund-Udenaes M; Hartvig P; Lindström L
    Soc Psychiatry Psychiatr Epidemiol; 2010 May; 45(5):523-9. PubMed ID: 19626260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial.
    Huhn M; Leucht C; Rothe P; Dold M; Heres S; Bornschein S; Schneider-Axmann T; Hasan A; Leucht S
    Eur Arch Psychiatry Clin Neurosci; 2021 Mar; 271(2):293-302. PubMed ID: 32062728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcome.
    Buchanan RW; Kreyenbuhl J; Zito JM; Lehman A
    Schizophr Bull; 2002; 28(1):63-73. PubMed ID: 12047023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients.
    Tuninger E; Levander S
    Acta Psychiatr Scand; 1997 Nov; 96(5):347-53. PubMed ID: 9395152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.